Status Proposed
Process STA
ID number 1076

Project Team

Project lead Jeremy Powell

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
03 July 2017 “This appraisal will be rescheduled because the company has let us know that with the currently available data, it is not possible to ascertain the drug’s cost-effectiveness with sufficient certainty. The company is expecting a data update in September of this year. This delay means that this topic will be removed from the NICE’s reporting targets for timeliness. In addition, through this request for delay the company accepts that this drug will not be eligible to receive interim funding from the date of marketing authorisation. ‘
05 December 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance